Stockwinners Market Radar for May 20, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:27 EDT AlTi Global CEO buys $461.2K in common stock - In a regulatory filing, AlTi Global disclosed that its CEO Stephen Girsky bought 100K shares of common stock on May 16th in a total transaction size of $461.2K.

20:05 EDT Cathie Wood's ARK Investment bought 90K shares of Crispr Therapeutics today

19:07 EDT Nicolet Bankshares raises quarterly dividend 12% to 28c per share - Nicolet Bankshares announced its Board of Directors has declared a quarterly cash dividend of 28c per share to shareholders of its common stock, an increase of 3c per share, or 12% over the prior quarter. The dividend will be payable on June 14, 2024 to shareholders of record as of June 3, 2024.

18:21 EDT Kontoor Brands CEO: Our company is doing really well - In an interview on CNBC's Mad Money, Scott Baxter said Kontoor has expanded its D to C and ecommerce businesses in a "significant way." The company has great brands at incredible value, he noted. It has been taking share for eight quarters. "We are starting to operate better globally," he added.

17:37 EDT RTX awarded $196.64M Defense logistics Agency contract - RTX has been awarded a maximum $196.64M firm-fixed-price, indefinite-delivery/indefinite-quantity contract for various tactical airborne navigation systems spare parts. This was a sole-source acquisition using 10 U.S. Code 3204 (a)(1), as stated in Federal Acquisition Regulations 6.302-1. This is a five-year base contract with one five-year option period. The performance completion date is May 19, 2029. Using military service is Army. Type of appropriation is fiscal 2024 through 2029 Army working capital funds. The contracting activity is the Defense Logistics Agency Land and Maritime.

17:25 EDT Forward Air names Jamie Pierson as interim CFO - Forward Air announced the appointment of Jamie G. Pierson as interim Chief Financial Officer effective May 20, 2024. Mr. Pierson succeeds Rebecca Garbrick, who is departing the Company. Ms. Garbrick will remain with the Company to assist with the transition. Mr. Pierson joins Forward having most recently served as Chief Financial Officer of MV Transportation, a privately-owned passenger transportation contracting services firm in North America, until January 2024. Forward has initiated a search for a CFO with the assistance of an executive search firm.

16:51 EDT AdvanSix CFO Michael Preston to retire - In a regulatory filing, AdvanSix (ASIX) disclosed that on May 20, Michael Preston notified AdvanSix of his intention to retire from his position as CFO during the 2024 fiscal year. Preston has served as the company's CFO since its spin-off in 2016 and, prior to the spin-off, had been with the predecessor company, Honeywell International (HON), since 2001. The company extends its gratitude to Preston for his many years of service and contributions to the company. Preston's decision to step down is not the result of any disagreement with the company on any matter relating to the company's operations, policies, or practices. The company has initiated a process to identify a successor. Preston plans to continue as CFO through the appointment of his successor, and will remain at the company through year-end 2024 to help facilitate the transition of his responsibilities.

16:33 EDT InfuSystem announces $20M stock buyback - InfuSystem "announced that the company's Board of Directors has approved a stock repurchase program authorizing the Company to repurchase up to $20 million of the Company's outstanding common stock through June 30, 2026. The program supersedes the previous authorization which was set to expire on June 30, 2024. Under the previous authorization, the Company repurchased approximately 550 thousand shares of stock for approximately $6.2 million."

16:32 EDT Simpson Manufacturing names Udit Mehta as Chief Technology Officer - Simpson Manufacturing (SSD) announced Udit Mehta has joined the company as Chief Technology Officer, effective May 10. Prior to joining Simpson, Mehta spent four years at Carrier Global (CARR) as the Chief Digital & Information Officer and GM Solutions for the Fire & Security segment.

16:31 EDT Curtiss-Wright selected to provide U.S. Airforce with networking technology - Curtiss-Wright "announced it has been awarded a $16 million contract by Iron Bow, acting as the prime contractor, to provide the U.S. Air Force with an integrated solution that provides optimization and improvement for deployable communications. Under the contract, Curtiss-Wright will provide the USAF with its PacStar(R) 400 series modules and Commercial Solutions for Classified integration. Curtiss-Wright's products have been approved to provide connectivity to Department of Defense Information Networks from anywhere in the world. In addition, Curtiss-Wright's solution will use software automation to improve connectivity and network security for multiple classification levels. The contract has an estimated lifetime value in excess of $60 million."

16:26 EDT Alamo Group announces end of strike at it subsidiary Gradall Industries - Alamo Group announced that on May 20 the strike that began on April 14 by unionized workers at its subsidiary, Gradall Industries located in New Philadelphia, Ohio, has ended. The approximately 200 workers part of the International Association of Machinists and Aerospace Workers, District Lodge 54, Local Lodge 1285, and the Company reached an agreement on a new five-year labor agreement.

16:22 EDT Transcat CEO says business to continue to benefit from recurring revenue in FY25 - The company states: "The Transcat team continues to deliver strong revenue growth and sustainable gross margin expansion as can be seen over the past decade and a half of profitable growth. As we think ahead into fiscal 2025, our business will continue to benefit from recurring revenue streams in highly regulated end markets, including life sciences, along with a growing Rentals business that performs well throughout various economic cycles. We expect another year of organic Service revenue growth in the high single-digit to low double-digit range when normalized for the extra week in fiscal 2024 and gross margin expansion. Automation of our calibration processes and overall process improvement will continue to be key enablers of future margin expansion."

16:18 EDT Phillips 66 to acquire Pinnacle Midstream for $550M - Phillips 66 announced it has agreed to acquire Pinnacle Midland Parent LLC from private equity firm Energy Spectrum Capital for cash consideration of $550M in a strategic move to expand its natural gas gathering and processing footprint in the Midland Basin. "We are growing our Midstream business in the Permian to further strengthen and expand our service offerings to customers while driving operational and commercial synergies," said Mark Lashier, Chairman and CEO of Phillips 66. "Pinnacle is a bolt-on asset that advances our wellhead-to-market strategy and complements our diversified and integrated asset portfolio. Further, this transaction aligns with our long-term objectives to build out our natural gas liquids value chain, be disciplined with our capital allocation and create sustainable value for our shareholders." Pinnacle's assets include the recently built Dos Picos natural gas gathering and processing system: a 220 MMcf/d gas processing plant, 80 miles of gathering pipeline and 50,000 dedicated acres through high-quality producers in one of Phillips 66's focus basins. The Dos Picos processing complex and related infrastructure is easily scalable toward a second 220 MMcf/d gas plant and integrates well into Phillip 66's existing downstream infrastructure. The transaction is expected to close around mid-year of 2024 following satisfaction of customary closing conditions, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

16:17 EDT Palo Alto Networks reports Q3 adjusted operating margin up 200 bps to 26%

16:16 EDT Palo Alto Networks reports Q3 remaining performance obligation up 23% to $11.3B

16:16 EDT FDA removes hold on Larimar 's nomlabofusp program for FA - Larimar Therapeutics announced the U.S. FDA has removed the partial clinical hold previously placed on the company's nomlabofusp CTI-1601 clinical program. Nomlabofusp is currently in development for the treatment of patients with Friedreich's Ataxia or FA . Nomlabofusp is a novel protein replacement therapy designed to address the root cause of FA by delivering frataxin to mitochondria. The FDA removed the partial clinical hold after a review of data from the Company's recently completed four-week, placebo-controlled Phase 2 dose exploration study. The review included data from both the 25 mg and 50 mg cohorts in patients who received daily dosing of nomlabofusp for 14 days followed by every other day dosing until day 28. "We are very excited the FDA has removed the partial clinical hold on our nomlabofusp program following review of our Phase 2 data. Helping patients with FA is our top priority and we appreciate the attention and thorough review by the FDA of all submitted data," said Carole Ben-Maimon, MD, President, and Chief Executive Officer of Larimar. "Importantly, we are now cleared to dose escalate to the 50 mg dose in our ongoing OLE study which we plan to do following further characterization of frataxin PD at the 25 mg dose. The OLE study is evaluating the long-term safety as well as frataxin levels following daily administration of nomlabofusp and we look forward to interim data in the fourth quarter of the year."

16:14 EDT Palo Alto Networks falls 9% to $295.00 after Q3 results, FY24 guidance

16:11 EDT Procaps Group discloses Nasdaq notice related to late filing of 20-F form - Procaps Group "announced that it has received a letter from the Nasdaq Stock Market, dated May 16, 2024, notifying the Company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because it did not timely file its annual report on Form 20-F for the year ended December 31, 2023. In accordance with Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Delinquency Letter to submit a plan to regain compliance with Nasdaq Listing Rules. If Nasdaq accepts the Compliance Plan, Nasdaq may grant the Company an extension until November 11, 2024 to regain compliance. If Nasdaq does not accept the Compliance Plan, the Company will have the opportunity to appeal that decision to the Nasdaq Hearings Panel."

16:10 EDT SunPower receives non-compliance letter from Nasdaq - SunPower received on May 17 a notice from The Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of all required periodic financial reports with the SEC, as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31 with the SEC, as described more fully in the Company's Notification of Late Filing on Form 12b-25 filed with the SEC on May 13. The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq. While the Company can provide no assurances as to timing, the Company is working diligently to finalize the 2023 Form 10-K and Q1 2024 10-Q and plans to file the 2023 Form 10K and Q1 2024 10-Q as soon as practicable to regain compliance with the Listing Rule.

16:09 EDT Tela Bio announces appointment of Greg Firestone as CCO - Tela Bio announced the appointment of Greg Firestone as the company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the company's product lines.

16:07 EDT Keysight Technologies falls 4% to $154.00 after Q2 results and guidance

16:04 EDT Alamo Group announces end of strike at Gradall Industries - Alamo Group "announced that on May 20, 2024 the strike that began on April 14, 2024 by unionized workers at its subsidiary, Gradall Industries LLC, located in New Philadelphia, Ohio, has ended. The approximately 200 workers part of the International Association of Machinists and Aerospace Workers, District Lodge 54, Local Lodge 1285, and the Company reached an agreement on a new five-year labor agreement."

16:02 EDT Nisun International receives non-compliance letter from Nasdaq - Nisun International Enterprise Development Group announced that it received a notice of non-compliance from Nasdaq Stock Market on May 17 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended December 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of the Company's Class A common shares on Nasdaq. Under Nasdaq's listing rules, the Company has 60 calendar days to submit a plan to regain compliance. If the plan is accepted by Nasdaq, the Company can be granted up to 180 calendar days from the Form 20-F's due date, or until November 11, 2024, to regain compliance. The Company is fully committed to regaining compliance and satisfying all of Nasdaq's listing requirements and working to file its Annual Report on Form 20-F as soon as practicable.

14:21 EDT Lenovo announces launch of Yoga Slim 7x and Lenovo ThinkPad T14s Gen 6 - Lenovo (LNVGY) announced the launch of the Lenovo Yoga Slim 7x and Lenovo ThinkPad T14s Gen 6, its first next generation Copilot+ PCs powered by Snapdragon X Elite. "As the PC industry enters a new phase of the artificial intelligence era, Lenovo is poised to offer new levels of personalization in personal computing across its PC portfolio. Intelligent software-powered local processing of tasks, and increased productivity, creativity, and security, these Copilot+ PC's combine to deliver a whole new experience in PC interaction. Lenovo is expanding its already comprehensive portfolio of AI-ready devices, software, and optimized services with two new laptops for consumers and business users," Lenovo said.

14:18 EDT Lennox to increase quarterly dividend to $1.15 from $1.10 per share - The board of directors of Lennox approved a 4.5% increase in the quarterly dividend from $1.10 to $1.15 per share of common stock, payable July 15, to stockholders of record as of June 28. "Our latest dividend increase is a result of consistently executing our strategy, driving margin improvements and generating solid cash flow. Our investments in expanded manufacturing capacity and sustainable products enhance our performance and competitiveness in the marketplace. We believe that our proactive growth and margin optimization strategies will continue to maximize value and deliver returns to our shareholders," said Lennox Chief Financial Officer Michael Quenzer.

14:15 EDT Microsoft unveils 7th Edition Surface Laptop and 11th Edition Surface Pro - Microsoft (MSFT) announced two new Copilot+ PCs: Surface Laptop, 7th Edition and Surface Pro, 11th Edition, the latest additions to our portfolio of devices available to our business customers. Built with the new Snapdragon X Elite and Plus processors from Qualcomm (QCOM) and Windows 11 Pro, these devices deliver the performance your teams need, are faster and have more AI acceleration than MacBook Air (AAPL), Microsoft said. These new Copilot+ PCs with integrated NPU bring new AI experiences such as Recall, Live Captions with Translations and new Windows Studio Effects help streamline everyday tasks, save valuable time and make it even easier to collaborate. The all-new Surface Laptop and Surface Pro are available to business customers in September, with pricing starting at $1,099.

14:12 EDT Microsoft calls new Surface Pro and Surface Laptop 'ultimate Copilot+ PCs' - Microsoft and Surface introduced what the company calls "the fastest, most intelligent Windows PCs ever: Copilot+ PCs." Microsoft added: "The all-new Surface Pro and Surface Laptop are the ultimate Copilot+ PCs, delivering incredible performance, all-day battery life and brand-new AI experiences. They showcase the beauty and innovation that happens at the intersection of software and hardware... Copilot+ PCs provide a quantum leap in computing, with power, performance and breakthrough AI experiences. Debuting with Snapdragon X Elite and Snapdragon X Plus processors, Copilot+ PCs are tuned to deliver optimal processing and response times - and are faster than the latest Macbook Air... The brand-new Surface Pro and Surface Laptop deliver incredible speeds, all-day battery life and all-new AI experiences, all starting at $999. You can pre-order today and learn more about our new products at Microsoft.com. They'll be available at key retailers worldwide starting June 18." Reference Link

14:09 EDT Dell expands 'Dell AI Factory' with Nvidia - Dell Technologies (DELL) announced it has expanded the Dell AI Factory with Nvidia (NVDA) to include new server, edge, workstation, solutions and services advancements that speed AI adoption and innovation. "Organizations are moving quickly to capture the AI opportunity, which is why our collaboration with NVIDIA is so important," said Michael Dell, founder and CEO, Dell Technologies. "Our expansion of the Dell AI Factory with NVIDIA continues our joint mission - we're making it easy for organizations to implement AI so they can move boldly into this next technological revolution. Generative AI requires a new type of computing infrastructure - an AI factory that produces intelligence. Together, NVIDIA and Dell are providing the world's industries with a full-stack offering - including computing, networking and software - that drives the copilots, coding assistants, virtual customer service agents and industrial digital twins of the digital enterprise."

14:04 EDT HP Inc. unveils new 'next-generation AI PCs' at Microsoft's AI Vision Event - HP Inc. (HPQ) unveiled "a new class of next-generation AI PCs" at Microsoft's (MSFT) AI Vision Event, the company announced. "The way we live and work is no longer confined to a desk; we are creating at home, from the office, and everywhere in between. At the same time, AI is rapidly changing everything, including consumer and professional expectations for productivity and creativity. More than half of early tech adopters believe AI will save them time5, and 72% of business leaders believe AI will help employees focus on more productive work.6 Additionally, developers are releasing a steady stream of AI-enabled software designed for new experiences and capabilities that can only be unlocked with next-gen AI PCs. To capitalize on both flexible work and AI, HP has created a new category of devices crafted for work and creation. Today, HP unveiled the HP OmniBook X AI PC and HP EliteBook Ultra AI PC, HP's first next-gen AI PCs built from the ground up with the latest ARM architecture to harness the most powerful AI technologies. Both devices are designed and engineered around the Snapdragon X Elite processor7 and its dedicated Neural Processing Unit (NPU)6, capable of 45 trillion operations per second to run language models and generative AI locally on the device. Coupled with Copilot+ PC and its transformative features like Recall, these PCs supercharge creativity and productivity for a more personalized, powerful computing experience," HP stated.

13:06 EDT Consolidated Water urges shareholders to vote for re-election of directors - Consolidated Water issued a statement commenting on the reports issued by Institutional Shareholder Services and Glass Lewis regarding the company's May 28, 2024 Annual General Meeting of Shareholders: "The Company strongly disagrees with the recommendations to withhold votes from Linda Beidler-D'Aguilar, Brian E. Butler and Leonard J. Sokolow for re-election to the Company's Board of Directors. The Company urges shareholders to vote "FOR" each of the nominees for election, including Ms. Beidler-D'Aguilar, Mr. Butler and Mr. Sokolow."

12:04 EDT San Juan Basin Royalty Trust falls -7.2% - San Juan Basin Royalty Trust is down -7.2%, or -31c to $3.99.

12:02 EDT GameStop falls -10.1% - GameStop is down -10.1%, or -$2.25 to $19.96.

12:01 EDT Overseas Shipholding rises 22.9% - Overseas Shipholding is up 22.9%, or $1.57 to $8.43.

12:00 EDT Hims & Hers rises 35.0% - Hims & Hers is up 35.0%, or $5.09 to $19.66.

11:48 EDT OLB Group regains compliance with Nasdaq minimum bid price rule - The OLB Group has received a written letter from Nasdaq, which has determined that for the last 10 consecutive business days, from May 6, 2024 to May 17, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

11:48 EDT JPMorgan sees Q2 investment bank fees up mid-teens vs. last year

11:47 EDT NY AG announces $2B settlement with crypto lender Genesis - New York Attorney General Letitia James secured a settlement worth $2B with bankrupt cryptocurrency firms Genesis Global Capital, Genesis Asia Pacific PTE, and Genesis Global Holdco, that will help maximize recoveries for investors who were defrauded. The settlement, which required review and approval by a bankruptcy court due to Genesis' previous bankruptcy declaration, will establish a victims fund to help defrauded investors, including at least 29,000 New Yorkers, who contributed more than $1.1B to Genesis through the Gemini Earn investment program. Additionally, the settlement bans Genesis from operating in New York. The settlement, the largest against a cryptocurrency company in state history, continues Attorney General James' work to increase oversight and regulation in this industry and protect New York investors, which has secured more than $2.5B from predatory cryptocurrency platforms to date. "When investors suffer losses because of fraud and manipulation, they deserve to be made whole," said Attorney General James. "This historic settlement is a major step toward ensuring the victims who invested in Genesis have a semblance of justice. Once again, we see the real-world consequences and detrimental losses that can happen because of a lack of oversight and regulation within the cryptocurrency industry. New York investors deserve the peace of mind that comes from a properly regulated marketplace, and that is something my office will always act to achieve." The settlement, which required bankruptcy court approval, will create a "Victims' Fund" for Genesis' creditors and resolves Attorney General James' claims against Genesis for defrauding hundreds of thousands of investors nationwide, including at least 29,000 New Yorkers. In October 2023, Attorney General James filed a lawsuit alleging that Genesis, along with other defendants, concealed more than $1.1B in losses from investors that provided digital assets through an investment program called "Gemini Earn." That lawsuit was expanded in February against Digital Currency Group, Genesis, DCG's CEO, Barry Silbert, and Genesis' former CEO, Soichiro Moro, for defrauding additional individuals and institutions of an additional $2B. Under this settlement, Genesis neither admits nor denies the allegations of this lawsuit, and the suit will continue against the remaining defendants, as well as Genesis' former business partner, Gemini Trust Company. Reference Link

11:40 EDT FTC finalizes order with Blackbaud related to security failure claims - The Federal Trade Commission has finalized an order against Blackbaud Inc. settling allegations that its lax security practices allowed a hacker to breach the company's network and access the personal data of millions of consumers including Social Security and bank account numbers. In a complaint first announced in February 2024, the FTC charged that the South Carolina firm, which provides data services and financial, fundraising, and administrative software services to companies, nonprofits and others, failed to implement appropriate safeguards to secure and protect the vast amounts of personal data it collects. As a result of these failures, a hacker in early 2020 exploited weaknesses in Blackbaud's networks, which went undetected for three months, allowing the hacker to remove massive amounts of unencrypted sensitive consumer data belonging to Blackbaud's customers. The company waited nearly two months to notify its customers about the breach and then misled consumers about the extent of the data that was stolen, according to the complaint. Under the order, Blackbaud is required to delete data that it no longer needs to provide its products or services and is prohibited from misrepresenting its data security and data retention policies. The order also requires Blackbaud to develop a comprehensive information security program that would address the issues highlighted by the FTC's complaint and put in place a data retention schedule outlining its data deletion practices. It also requires Blackbaud to notify the FTC if it experiences a future data breach that it is required to report to any other local, state, or federal agency. After receiving two comments, the Commission voted 3-0-2 to give final approval to the settlement. Commissioner Andrew Ferguson did not participate and Commissioner Melissa Holyoak was recused.

11:31 EDT Instacart says does not expect to exceed GTV guidance - Says wants to be able to deliver on EBITDA "with some flexibility." Comments made by CFO Emily Reuter at the J.P. Morgan Global Technology, Media and Communications Conference.

11:03 EDT Fermata, Xcel Energy announce vehicle-to-everything bidirectional charging pilot - Fermata Energy, Xcel Energy, City of Boulder, Colorado CarShare and Boulder Housing Partners announced a collaborative Vehicle-to-Everything bidirectional charging pilot project at Boulder Housing Partners' 30 Pearl development and the Molly's Spirits Lakeside facility. This innovative V2X pilot program transforms parked EVs into mobile power units, advancing grid resilience and reducing electric bill costs while supporting underserved communities and local businesses.

10:04 EDT Huya rises 13.0% - Huya is up 13.0%, or 78c to $6.78.

10:03 EDT Hims & Hers rises 18.6% - Hims & Hers is up 18.6%, or $2.71 to $17.28.

10:01 EDT Oklo falls -5.5% - Oklo is down -5.5%, or -50c to $8.51.

10:00 EDT San Juan Basin Royalty Trust falls -9.8% - San Juan Basin Royalty Trust is down -9.8%, or -42c to $3.88.

09:58 EDT JPMorgan says strategies enabling deposit share gains over time - Says outperformed peers in deposit growth since 2019. Says deposit share gains widespread. Says branch expansion "contributing meaningfully" to outperformance, with more upside as branches mature. Says target is 15% national retail deposit share, with further upside.

09:51 EDT TAL Education falls -4.5% - TAL Education is down -4.5%, or -58c to $12.35.

09:49 EDT San Juan Basin Royalty Trust falls -7.2% - San Juan Basin Royalty Trust is down -7.2%, or -31c to $3.99.

09:48 EDT JPMorgan sees 2024 CCB investments ~$9B - Says consumer financial health has largely normalized, remains stable. Says small businesses remain "financially healthy." Says credit has normalized. Expects loss rates to remain "relatively stable." Says "operating from a position of strength" and "prepared for a range of outcomes." Says medium term guidance remains at 25%+ ROE through the cycle.

09:47 EDT Overseas Shipholding rises 22.7% - Overseas Shipholding is up 22.7%, or $1.55 to $8.41.

09:39 EDT Sonnet BioTherapeutics announces updated clinical data for SON-1010 - Sonnet BioTherapeutics Holdings announced that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials and the Company is now increasing the target dose of SON-1010 during dose escalation. SON-1010 is a proprietary version of recombinant human interleukin-12, configured using Sonnet's Fully Human Albumin Binding platform, which extends the half-life and activity of the IL-12 component due to binding native albumin in the serum and targets the tumor microenvironment by strongly binding gp60 and Secreted Protein Acidic and Rich in Cysteine. SB101 is a Phase 1 multiple-ascending dose trial in adult patients with advanced solid tumors that commenced in Q2 2022 and is currently enrolling the sixth dose cohort. SB221 is a Phase 1b/2a dose-escalation and proof-of-concept study of the combination of SON-1010 with atezolizumab, in a study focused on platinum-resistant ovarian cancer that started in Q4 2023, now enrolling the fourth dose cohort. In addition, SON-1010 was studied in SB102, which was a Phase 1 single-ascending dose trial in healthy volunteers that started in Q3 2022; the results were recently published. Safety in both of the active cancer trials has been reviewed by their respective Safety Review Committees at each step during dose escalation. Both trials use a 'desensitizing' first dose to take advantage of the known tachyphylaxis with rhIL-12, which minimizes toxicity and allows higher maintenance doses. No dose-limiting toxicities or related serious adverse events have occurred to date. The safety and toxicity profile that has developed is typical for a Phase 1 oncology trial, with the majority of adverse events being reported as mild. All have been transient, with no evidence of cytokine release syndrome. Of the 25 cancer patients dosed to date and evaluable for follow-up at this latest cutoff, 15 had stable disease at their first follow-up scan, 8 of whom were progressing at study entry. At four months follow-up, 8 of 23 evaluable patients remained stable at the second CT scan, suggesting clinical benefit of SON-1010 in 35% of the patients. One patient with progressive endometrial sarcoma receiving SON-1010 monotherapy in SB101 had stable disease for almost 2 years before progressing - her ascites had resolved and tumors had shrunk at one point but she never reached a partial response by Response Evaluation Criteria in Solid Tumors rules. Cytokine analysis following each dose in that study revealed controlled and prolonged induction of interferon gamma that peaked at 24 to 48 hours and returned to baseline within 2 to 4 weeks. A small increase in IL-10 was observed with each dose as expected in response to IFNgamma. There was either a minimal or no signal for IL-1beta, IL-6, IL-8, and TNFalpha, and there was no indication of any potential for cytokine release syndrome at these doses. One patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have received 8 and 10 cycles, respectively, and are continuing on the study. The stable AE profiles despite dose escalation led us to reevaluate the target dose, so the Company has added groups in both studies to evaluate 1200 ng/kg SON-1010 as a maintenance dose. Finally, Part 2 of the SB221 combination study has been trimmed to remove the monotherapy arm.

09:32 EDT Jeffs' Brands signs MOU to acquire company operating logistics center - Jeffs' Brands announced the signing of a memorandum of understanding to acquire a company that operates a strategically located logistics center in New Jersey. Pursuant to the MOU, the potential acquisition encompasses a 100,000-square-foot facility equipped with 20 loading docks, poised to significantly enhance the Company's supply chain capabilities. Situated near the second largest port in the U.S., as well as in close proximity to Newark and JFK Airports, this facility is ideally positioned to support Jeffs' Brands' rapid growth and expansion. The center's strategic location has the potential to facilitate efficient transport and logistics operations, vital for maintaining the speed and reliability needed in today's fast-paced e-commerce environment.

09:30 EDT Atara Biotherapeutics submits BLA to FDA for tabelecleucel - Atara Biotherapeutics announced that Atara has submitted a biologics license application, or BLA, to the FDA for tabelecleucel indicated as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. There are no FDA approved therapies in this treatment setting.

09:16 EDT Danimer Scientific CEO Stephen Croskrey to retire not later than 2024-end - Danimer Scientific announced that Stephen Croskrey has informed the Board of Directors that he will retire as Chief Executive Officer not later than the end of this calendar year. Mr. Croskrey's employment contract expires at the end of 2024 following nine years leading Danimer's mission to commercialize its innovative biodegradable plastic resin, Nodax PHA. Mr. Croskrey has led Danimer through the process of becoming a public company by merging with Live Oak Acquisition Corp in 2020. During Mr. Croskrey's tenure, Danimer has acquired and expanded its Winchester, KY plant, which is now capable of producing over 32.5 million pounds of neat PHA or about 65 million pounds of finished product. Danimer currently supplies the resin for biodegradable and compostable drinking straws used by leading brands including Starbucks as well as the broadly distributed Phade brand of straws made by Wincup. Recently, the Company has also begun supplying resin for use in compostable plastic cutlery for a leading quick serve restaurant chain and for coffee pods sold in Europe.

09:10 EDT H.B. Fuller acquires adhesives, sealing solutions firm ND Industries, no terms - H.B. Fuller announced that it has acquired ND Industries provider of specialty adhesives and fastener locking and sealing solutions serving customers in the automotive, electronics, aerospace, and other industries. The acquisition is expected to accelerate the realization of H.B. Fuller's top growth priorities, consistent with the company's strategy to proactively drive capital allocation to the highest margin, highest growth market segments within the functional coatings, adhesives, sealants and elastomer CASE industry. As part of the acquisition, products under ND Industries' Vibra-Tite brand will be added to H.B. Fuller's existing epoxy, cyanoacrylate, UV curable and anaerobic product range. "ND Industries has been a very profitable, family-owned business for several decades and has impressively built one of the most extensive product portfolios in the pre-applied fastener industry," says President and CEO Celeste Mastin. "Their products are a natural fit with our existing market segments and bring new technology to our portfolio - combining the benefits of an adhesive and a mechanical fastener within extremely demanding applications - resulting in a powerful advantage for our customers."

09:07 EDT Grayscale CEO Michael Sonnenshein steps down - In a regulatory filing, Grayscale Investments, the sponsor of Grayscale Bitcoin Trust (GBTC), announced that it has approved the appointment of Peter Mintzberg to serve as Grayscale's new CEO and the principal executive officer of the company, and a member of the Board of Directors of Grayscale, effective August 15, 2024. Mintzberg will succeed Michael Sonnenshein, the current CEO of Grayscale and the principal executive officer of the company, who has decided to step down from his position, effective immediately. Edward McGee, the CFO of Grayscale and principal financial officer of the company, will serve as principal executive officer on an interim basis until Mintzberg's commencement date. Mintzberg joins Grayscale from Goldman Sachs (GS) where he currently holds the position of Global Head of Strategy for Asset and Wealth Management.

09:04 EDT Heart Test announces internationalization of its AI-ECG patent portfolio - Heart Test Laboratories announced that it has been granted Indian Patent Application 201817014481 by the Indian Patent Office, IPO. To date, HeartSciences has been granted nine US patents and 35 international patents for a total of 44 granted patents. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, UK, Italy and the Netherlands.

09:03 EDT Broadcom announces latest portfolio of 400G PCIe Gen 5.0 Ethernet adapters - Broadcom announced its latest portfolio of highly-scalable, high-performing, low-power 400G PCIe Gen 5.0 Ethernet adapters to revolutionize the data center ecosystem. These latest products offer an enhanced, open, standards-based Ethernet NIC and switching solution to resolve connectivity bottlenecks as XPU bandwidth and cluster sizes grow rapidly in AI data centers. As the industry's first Ethernet adapter built with 5nm process technology, the new portfolio enables the most power and thermally efficient design in the market. Combined with the device's ability to drive passive copper cables up to five meters or ultra-low power linear pluggable optics transceivers and Broadcom's high-radix Ethernet switches, the adapter delivers higher rack density using mainstream air-cooling technology.

09:02 EDT LPL Financial: Cornerstone joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Lance Dumas and Darryl Carter CPA, have joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported serving approximately $225 million in advisory, brokerage and retirement plan assets and join LPL from Cetera. Based in Orange County, Calif., Dumas and Carter founded Cornerstone Financial Advisers in 2017 as a consulting firm dedicated to helping families, individuals and business owners establish their goals and create financial plans to pursue them. Dumas has 25 years of experience in the financial services industry, including key leadership roles at national financial institutions. Carter, who has nearly 30 years in tax and wealth management services, sold his tax practice last year to focus solely on his investment clients. They are joined by Office Manager Nicole Thornton.

08:58 EDT Syra Health awarded services contract by South Carolina school district - Syra Health has been awarded a one-year contract with annual extensions for up to five years to provide Special Education Psychologist Services for the Greenville County School District in South Carolina. Per the contract, Syra Health will provide ongoing SPED psychologist services to support student's academic progress, social and emotional learning, and behavioral needs through data-based decision-making, assessment tools, and the delivery of evidence-based interventions. The Greenville County School District has approximately 80,000 students and 13,000 employees.

08:55 EDT Evolus announces positive topline results in NLF study - Evolus announced positive topline results from a U.S. pivotal nasolabial fold or NLF, study of dermal filler products Evolysse Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, in Nashville. "Achieving positive topline results in our NLF study is a pivotal step supporting the upcoming submission of our Premarket Approval application for the U.S. launch of our dermal filler lines. Complementing our flagship neurotoxin Jeuveau, the fastest growing neurotoxin in the U.S. for the past three years1 - our Evolysse line of dermal fillers expands our total addressable market by 78%," said David Moatazedi, President and Chief Executive Officer... The 6-month primary endpoint measured the change in NLF severity from baseline and was assessed by a blinded independent photographic review panel using a validated 5-point nasolabial scale.

08:52 EDT Mawson Infrastructure reports April monthly revenue $4.85M - Unaudited April Monthly Operating Results Summary: Total monthly revenue increased 65% Y/Y to about $4.85 million and the equivalent of 74 BTC. Self-mining business revenue increased 73% Y/Y to $1.92 million. Co-location business revenue increased 105% Y/Y to $2.87 million. Recently announced co-location expansion agreement increased Mawson's co-location services capacity to approximately 82 MW and over 25,872 miners. Total power capacity across Company's facilities approximately 109 MW with capacity for approximately 35,650 miners. Company announced plans to expand its Midland facility by 20 MW, increasing the Company's future total capacity to approximately 129 MW and about 41,530 miners. Rahul Mewawalla, CEO and President, commented, "We are pleased with another strong month of year-over-year growth with our total overall revenue growing 65% this April over last year, driven by operational focus and execution across our self-mining and co-location services businesses. We drove growth in our self-mining business revenue by 73% and our co-location business revenue by 105% this April as compared to last year. We were also excited to announce plans to expand our Midland facilities by an additional 20 MW that should drive additional growth and customer expansion opportunities for our co-location services business. We believe our focus on operations, technology, and strategic transformation will further advance our role in the industry and our ecosystem."

08:49 EDT MultiMetaVerse to acquire e-commerce service provider Bowong AI - MultiMetaVerse has entered into a non-binding term sheet for the acquisition of 100% of Bowong Technology and its subsidiaries by the issuance of the company's Class A ordinary shares to the shareholders of Bowong AI as consideration, the amount of which will be determined based on further due diligence and negotiation. The consideration shares shall be subject to a lock-up period of one year. MMV has an exclusive period of 90-day to negotiate a definitive agreement for the proposed transaction. Founded in 2022, Bowong AI is an artificial intelligence company specializing in e-commerce solutions. Combined with its AI-powered content distribution algorithm, Bowong AI is able to produce and distribute personalized marketing contents in different forms for the goods across all platforms in a short time. Recently, Bowong AI has completed its Series A funding of several million dollars. The proceeds will be used to further develop its models and technologies in the e-commerce field, expand its market into Asia and North America, and recruit additional top talents.

08:48 EDT JPMorgan says excess capital supports increased buybacks, but remains cautious - Sees ~$78B of excess capital as of 1Q25. Does not see "compelling opportunities" to deploy capital. Says despite expected soft landing, risks and uncertainties remain. Expects returns to normalize over next few years.

08:45 EDT P10 says RCP Fund XVIII closes on $285M in aggregate capital commitments - P10 announced that its affiliated manager, RCP Advisors announced the final closing of RCP Fund XVIII. The Fund has a broad LP base of new and existing investors, including family offices, high-net-worth individuals, foundations, public pension plans, and endowments. The Fund will generally target investments with buyout fund managers focused on less than $1 billion in committed capital. These managers will, in turn, generally seek to make control-oriented investments in established, small to mid-sized companies with approximately $3 million to $25 million in EBITDA.

08:44 EDT iPower's SuperSuite Supply Chain celebrates first anniversary - iPower announced the first anniversary of its SuperSuite supply chain business and key differentiators fueling its transformative growth. "Since its inception in 2023, SuperSuite has emerged as a critical partner for innovative product companies looking to expand their omnichannel presence, enabling them to accelerate their sales growth and brand recognition," said Lawrence Tan, CEO of iPower. "We're pleased with SuperSuite's strong sales momentum in recent months, as it now accounts for approximately 10% of revenue and contributed to iPower's return to profitability in our fiscal third quarter of 2024. We are working through a robust pipeline of top-tier partners and look forward to capitalizing on the growing demand for SuperSuite as it becomes an even larger contributor to our revenue mix."

08:43 EDT Owens-Brockway Glass Container launches $300M senior notes offering - Owens-Brockway Glass Container intends to offer, subject to market and other conditions, $300 million aggregate principal amount of its senior notes due 2032 in a private offering to eligible purchasers under Rule 144A and Regulation S of the U.S. Securities Act of 1933, as amended. OBGC's obligations under the Notes will be guaranteed on a joint and several basis by Owens-Illinois Group and certain U.S. domestic subsidiaries of OI Group that are guarantors under OI Group's credit agreement. OBGC expects to use the net proceeds from the Offering, together with cash on hand, to redeem all of OBGC's outstanding 6.375% Senior Notes due 2025.

08:41 EDT Shimmick announces key actions to enhance liquidity - Shimmick Corporation (SHIM) announced that it has taken several key actions to enhance liquidity and deliver on its transformation into a water infrastructure company. As previously announced, Shimmick has signed an asset purchase agreement for the sale of its foundation drilling assets for a total consideration of $17.5 million. Closing of the agreement is expected by the end of this week. Shimmick has entered into an amendment to its existing credit facility with MidCap, which, among other things, cures the previously disclosed default. As a result, Shimmick expects to file its Quarterly Report on Form 10-Q for the quarter ended March 29, 2024, today, May 20, 2024, with no changes to its previously announced financial results. Shimmick has entered into agreements with AECOM (ACM) to resolve the ongoing lawsuit relating to the purchase and sale agreement for the divestiture of Shimmick from AECOM in exchange for shares in Shimmick. Peter Kravitz will join the board as a new independent member and as a member of a newly formed Board of Directors special committee to oversee efforts to enhance the long-term value of the Company. Finally, Shimmick has entered into a new, $60 million revolving credit facility. "Today's announcements accelerate the transformation of Shimmick as a leader in the U.S. water infrastructure space," said Steve Richards, CEO. "The settlement, the asset sale and the incremental debt financing enhance liquidity as we complete legacy projects, with the substantial cash recoveries expected this year as we also vigorously pursue claims and change orders that are expected to deliver substantial cash inflows. And lastly, we are excited to welcome Peter Kravitz to our Board."

08:40 EDT Braemar Hotels & Resorts releases presentation on Monty Bennett - Blackwells Capital, a shareholder of Braemar Hotels & Resorts, released a presentation entitled "The Buffoonery of Monty Bennett." Jason Aintabi, Chief Investment Officer of Blackwells, said: "Last week, Mr. Bennett expanded his comically inept smear campaign designed to keep independent directors out of Braemar's boardroom. Following Blackwells' report that Mr. Bennett's social media account had a mere four followers, it would appear that Mr. Bennett scrambled to direct the purchase of over 3,000 fake followers for his account. Blackwells will fight to ensure that all monies, great and small, that are spent to satisfy Mr. Bennett's buffoonery are recovered and returned to shareholders. We continue to pursue the termination of Braemar and Mr. Bennett's shady Advisory Agreement for cause, and will hold the Company's board accountable for abetting what we believe is one of the most grotesque examples of corporate piracy in the public markets today."

08:39 EDT Worlds Inc. signs LOI with Jordan Freeman Group - Worlds has signed a Letter of Intent, LOI, with Jordan Freeman Group - ZOOM Platform to license the ZOOM Platform DRM-Free online entertainment platform and portfolio of classic video games. ZOOM Platform is not related to the Zoom video conferencing platform. Additionally, the LOI includes Worlds licensing upcoming original intellectual properties, such as Shadow Stalkers and MegaRace: DeathMatch. The LOI also includes licenses to Wanderful Interactive intellectual properties, originally published as Living Books, based on the works of award-winning authors including Marc Brown, Dr. Seuss, Stan & Jan Berenstain, Mercer Mayer, and other popular children's book authors. The LOI is subject to negotiation and execution of definitive agreements. No assurance can be given that an agreement will be reached.

08:37 EDT Lixte Biotechnology provides update on recent activities - LIXTE Biotechnology Holdings provided an update on the Company's recent activities, including notable pre-clinical developments. Recent Company highlights include: Pre-clinical studies in a new field of cancer biology -- activation lethality -- have shown that LB-100 can force cancer cells to give up their cancer-causing properties. The findings open a potentially new treatment strategy in addition to LIXTE's current three ongoing clinical trials. Bas van der Baan, LIXTE's President and Chief Executive Officer, presented at the MedInvest Biotech and Pharma Investor Conference on April 3, 2024 in New York City. The two-day event featured presentations from more than 40 companies, developing and commercializing technologies across a broad spectrum of indications, including oncology. LIXTE co-sponsored an international scientific workshop on "Therapeutic Over-Activation in Cancer" at Harvard University's Dana Farber Cancer Institute in Boston, Massachusetts on May 9 and 10, 2024. The workshop brought together leading experts from the pharmaceutical industry and academia who discussed a radically different approach to cancer therapy that is being spearheaded by LIXTE's outsourced research team at the Netherlands Cancer Institute.

08:36 EDT Star Equity completes acquisition of Timber Technologies - Star Equity Holdings has completed the acquisition of Timber Technologies, a Wisconsin-based engineered wood products manufacturer, effective May 17, 2024. Transaction Highlights: $23 million cash-free, debt-free purchase price. $23 million includes: $16 million in upfront cash; $4 million in deferred cash; and a $3 million, 2-year earn-out payable 50% in cash and 50% in shares of STRRP preferred stock. Earn-out Adj. EBITDA targets are $5.4 million and $6.0 million for years 1 and 2, respectively. Associated real estate will be acquired in June 2024 for $3 million in a separate transaction. Closed $7 million term loan from Bridgewater Bank to partially finance the acquisition. Co-Owners/Operators, Tom Niska and Dale Schiferl, will stay with the business in their current roles. Founded in 2003, Timber Tech manufactures glue-laminated timber products for various end markets and applications, including agriculture, industrial, infrastructure, and building construction. Its glulam products have superior strength, durability, and environmental sustainability compared to solid timber and other building materials. Operating in a niche industry and benefiting from secular tailwinds, Timber Tech's glulam products have been taking market share from less sustainable building materials such as steel, concrete, and aluminum. Timber Tech will continue its operations as part of Star's Building Solutions division, which operates alongside Star's Investments division. As a diversified holding company, both of Star's divisions will continue to pursue growth opportunities through both organic growth and acquisitions. Timber Tech operates a 69,000 square foot facility in Colfax, WI. Star will also acquire this associated real estate in a separate transaction expected to close in June 2024. Star expects to issue a $3 million seller note to finance the purchase of the real estate. The seller note will bear a fixed interest rate of 7.5% and amortize over ten years. Simultaneous with the closing of the Timber Tech acquisition, Star also closed a $7 million term loan with Bridgewater Bank to partially finance the acquisition. This acquisition term loan bears a fixed interest rate of 7.85% and amortizes over five years. Star issued a total of 90,000 RSUs from its 2022 Inducement Stock Incentive Plan to three Timber Tech employees at the closing of the acquisition.

08:34 EDT eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute - eFFECTOR Therapeutics announced a collaboration to conduct an investigator-sponsored trial evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at DFCI, and an Associate Professor of Medicine at Harvard Medical School.

08:29 EDT JPMorgan sees 2024 total NII ex ~$91B, up from prior view of ~$90B - Comments from Investor Day presentation.

08:23 EDT Gray Television announces private offering of senior secured notes - Gray Television intends to offer up to $1 billion aggregate principal amount of senior secured first lien notes due 2029, subject to market conditions. The offering will be exempt from the registration requirements of the Securities Act of 1933. In connection with the offering of notes, Gray expects to incur up to $750 million of a new tranche F term loan with a maturity date in 2029, increase the aggregate commitments under its existing $625 million revolving credit facility by $55 million, resulting in aggregate commitments under the revolving credit facility of $680 million and terminate commitments under a $72.5 million tranche of the revolving credit facility maturing in 2026. The closing of this offering of notes is conditioned on the closing of the Credit Agreement Refinancing, and the closing of the Credit Agreement Refinancing is conditioned on the closing of this offering. The completion of the Credit Agreement Refinancing is subject to market and other conditions and there can be no assurance as to whether or when the Credit Agreement Refinancing may be completed, if at all. The notes are being offered, together with the net proceeds of the new tranche F term loans, availability under its revolving credit facility and cash on hand, to refinance Gray's $1.2 billion tranche E term loan due 2026, repurchase in a tender offer any and all of its outstanding 5.875% senior notes due 2026 and pay all fees and expenses in connection with the offering. The notes will be guaranteed, jointly and severally, by each existing and future restricted subsidiary of Gray that guarantees Gray's existing senior credit facility.

08:21 EDT Exelixis announcess settlement of cabozantinib patent litigation with Cipla - Exelixis announced that it has entered into a Settlement and License Agreement with Cipl and Cipla USA, . This settlement resolves two patent litigations brought by Exelixis in response to Cipla's Abbreviated New Drug Application ANDA seeking approval to market generic versions of CABOMETYX or cabozantinib tablets prior to the expiration of the applicable patents. The first case filed on March 16, relates to Cipla's ANDA for a 60 mg cabozantinib dosage strength. filed on May 9 relates to a recent amendment to Cipla's ANDA, for the primary purpose of seeking additional approval for 20 mg and 40 mg cabozantinib dosage strengths. Pursuant to the terms of the Agreement, Exelixis will grant Cipla a license to market generic versions of CABOMETYX in the United States beginning on January 1, 2031, if approved by the U.S. Food and Drug Administration and subject to conditions and exceptions common to agreements of this type. Additionally, in accordance with the Agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Exelixis and Cipla regarding CABOMETYX patents pending in the U.S. District Court for the District of Delaware. The Agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. The lawsuits will be dismissed after a period of time to allow for FTC review.

08:17 EDT Ameresco awarded $21M contract to illuminate Henderson Nevada streets - Ameresco announced its collaboration with the City of Henderson to upgrade street lighting infrastructure with state-of-the-art LED technology. The $21M project, awarded to Ameresco, marks a significant step towards enhancing safety, energy efficiency, and community well-being. "We're honored to continue our decade-long partnership with the City of Henderson and contribute to the community's advancement," said Lou Maltezos, Executive Vice President, at Ameresco. "Sustainable urban development should not only prioritize progress but also enrich the quality of life for residents and our team is thrilled to be helping them achieve both."

08:16 EDT PetMed Express appoints Mennen to board of directors - PetMed Express (PETS) announced the appointment of Justin Mennen to the Company's Board of Directors, effective June 3, 2024. Mennen brings over 25 years of technology experience to the Company. Mennen has had an extensive career in technology leadership, including his tenure as an executive officer at Rite Aid Corporation (RAD) from January 2019 to July 2023.

08:14 EDT Rumble announces launches podcast 'Breaking Points' - Rumble announced that the podcast "Breaking Points" is making Locals and Rumble its new subscription provider. The full show will be available to paying community members on Locals, Rumble's subscription platform, where paying subscribers will have members-only access along with the ability to participate in weekly Q&A sessions. The new partnership will also feature exclusive "Breaking Points" content on Rumble, which will be available to the general public.

08:14 EDT MarineMax promotes Manny Alvare to General Counsel - MarineMax announced the promotion of Manny Alvare, the Company's Vice President of Legal Affairs since October 2021, to the position of General Counsel. Mr. Alvare joined MarineMax as Corporate Counsel in 2018 after a distinguished career serving as in-house counsel for several Florida companies in a wide range of industries. During his tenure at MarineMax, he has overseen the legal work related to the Company's acquisitions, brand expansions, domestic and international growth, and numerous other strategic initiatives. Mr. Alvare is a graduate of the University of Florida and received his law degree from St. Thomas University's Benjamin L. Crump College of Law.

08:12 EDT Mainz Biomed unveils key findings from eAArly DETECT study - Mainz Biomed unveiled key findings from its eAArly DETECT study during a poster presentation at the renowned Digestive Disease Week, DDW, 2024 in Washington D.C. The Company was awarded as a Poster of Distinction by the Digestive Disease Week judges. The poster titled 'Novel Stool-based non-invasive early detection of colorectal cancer and precancerous lesions by classic FIT combined with nucleic acid-based biomarker signatures' was presented by Dr. Lena Krammes, Senior Scientist at Mainz Biomed. Key findings of the eAArly DETECT clinical study include a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%. Additionally, the data demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected. Only one of the colorectal cancer patients was not detected at stage I of the disease. Resulting performance data confirms the outcome previously obtained from the separate European ColoFuture study and that this multimodal screening strategy reflects a substantial and meaningful improvement for CRC and especially AA detection, where improved sensitivity is urgently needed to decrease CRC incidence and mortality

08:11 EDT NKGen Biotech's SNK01 NK Cell Therapy cleared to start Phase 2 trial - NKGen Biotech announced that its Safety Review Committee has cleared the Company's cryopreserved autologous, expanded and enhanced SNK01 to progress into Phase 2 clinical development. NKGen's initial "proof of concept" Phase 1 study was an open label, 3+3 dose escalation study which demonstrated that even after only four doses given simple IV, that SNK01 was very safe and able to cross the blood brain barrier to reduce amyloid, tau, and alpha-synuclein proteins as well as neuroinflammation in a dose responsive manner. Despite only receiving four doses, 90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score. Based on this initial pilot experience, NKGen received US FDA clearance for a new Phase 1/2a study in moderate Alzheimer's disease using its new cryopreserved autologous product at an increased dose of 6 billion cells given every three weeks for a full-year compared to only four total doses in the initial proof-of-concept study.

08:09 EDT NextPlat subsidiary Global Telesat named Starlink global reseller - NextPlat subsidiary Global Telesat Communications, or GTC, through a new joint venture agreement with Pivotel Solutions, is now a global authorized reseller of SpaceX's Starlink satellite-based connectivity products. Through the joint venture agreement with Pulsar, as an approved reseller, GTC will immediately begin offering Starlink connectivity services in the UK and other international markets serving mobile and maritime-based customers. Pulsar will provide back-end systems support services to GTC on behalf of its new Starlink customers.

08:08 EDT Allarity regains compliance with Nasdaq minimum stockholder equity requirement - Allarity Therapeutics announced that it has received formal written notice from The Nasdaq Stock Market's Office of General Counsel that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). This confirmation follows the Company's successful efforts to cut operation costs and improve its balance sheet, including raising new equity and reducing outstanding liabilities. Thomas Jensen, CEO of Allarity Therapeutics, stated, "We are very pleased to announce that Allarity has regained compliance with Nasdaq's equity requirement. During our panel hearing with Nasdaq in February this year, we presented a strategic plan to achieve this goal, and I am satisfied to note that we have successfully delivered on our commitments and received formal confirmation from Nasdaq. This allows us to continue focusing on our mission to advance our lead asset, stenoparib, toward regulatory approval with the aim of bringing this promising therapy to patients in need of new treatment options for advanced ovarian cancer."

08:07 EDT NV5 Global announces acquisition of myBIMteam - NV5 Global announced that it has acquired myBIMteam. Founded in 2003, myBIMteam provides full-service building digitization services on a subscription basis to building owners, facility managers, and architects to support asset management and improve the energy efficiency and productivity of facilities. The acquisition was made with a combination of cash and stock and will be immediately accretive to NV5's earnings. "NV5 continues to invest in high-growth technology and tech-enabled services that deliver scalability and barriers to entry, while accelerating organic growth and profitability," said Dickerson Wright, PE, Executive Chairman of NV5. "MyBIMteam's subscription-based service delivery model supports NV5's strategic focus on expanding recurring and subscription-based services that facilitate long-term client relationships and organic growth."

08:06 EDT Bumble to acquire Geneva, terms undisclosed - Bumble announced its intention to acquire Geneva, the group and community app for people to connect based on shared interests. Through the planned acquisition of Geneva, Bumble Inc. aims to rapidly expand the Bumble For Friends experience from one-to-one connections to groups and communities to serve the many ways people seek friendships. The acquisition is anticipated to close in Q3 2024, subject to customary closing conditions.

08:06 EDT Kairous Acquisition announces additional contribution to trust account - Kairous Acquisition Corp. announced that Kairous Asia Limited, the Company's initial public offering sponsor, has deposited into the Company's trust account an aggregate of $50,000, in order to extend the period of time the Company has to complete a business combination for an additional one month period, from May 16, 2024 to June 16, 2024. The Company issued a promissory note to Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and will be converted into the Company's ordinary shares at a price of $10.10 per share at the closing of a business combination by the Company. The purpose of the extension is to provide time for the Company to complete a business combination.

08:05 EDT Mira Pharmaceuticals advances new preclinical studies using Ketamir-2 - Mira Pharmaceuticals announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder and other leading mental health disorders and neuropathic pain indications. Mira continues to advance studies of Ketamir-2 in animal studies while improving manufacturing optimization as the company prepares for human testing in 2025. Mira anticipates that positive results from these preclinical studies will enable the submission of an Investigational New Drug Application to the U.S. FDA by the end of this year, which if cleared by FDA would allow for human clinical testing of Ketamir-2.

08:03 EDT Standard BioTools announces inducement grant under Nasdaq listing rule - Standard BioTools announced that the Human Capital Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of May 20, 2024, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan. The equity award consisted of an award of 207,832 restricted stock units as a material inducement to a new employee entering into employment with Standard BioTools. The RSU award was approved in accordance with Nasdaq Listing Rule 5635(c)(4). With respect to the RSUs, 1/4th of the total number of shares of common stock underlying the RSUs will initially vest on May 20, 2025 and 1/16th of the shares underlying the RSUs will vest every three months after the initial vesting date until fully vested; provided, however, that if a vesting date would otherwise fall on a day when the national stock exchange upon which the shares are listed is not open for trading, vesting will occur on the first trading day thereafter. Vesting in all instances is subject to the new employee's continued service with Standard BioTools through each applicable vesting date, in addition to the other terms and conditions of the Plan and the RSU agreement covering the grant.

08:01 EDT authID announces Annual Meeting of Stockholders - authID announced that its 2024 Annual Meeting of Stockholders will be held virtually on June 26, at 10:00 a.m. EDT. At the meeting, proposals will be submitted to elect directors, ratify the appointment of auditors, reduce the number of authorized shares in order to save expenses, ratify the adoption of the 2024 Equity Incentive Plan and approve "Say-on-Pay" and "Say-on-Pay" frequency resolutions. The Company is proposing the election of all of the current seven directors. The Company has filed its Proxy Statement with the SEC, which explains all the proposals and provides other information about the Company, and is mailing the Notice of Meeting, the Proxy Statement and additional materials related to the Annual Meeting to stockholders. Stockholders who hold their shares through brokerage accounts will receive the materials via their brokers, either through the mail, or electronically depending on their communication preferences.

07:43 EDT Glass Lewis recommends Hess shareholders vote for proposed merger with Chevron - Hess (HES) announced that independent proxy voting and corporate governance advisory firm Glass, Lewis has recommended that Hess shareholders vote FOR the proposed merger with Chevron (CVX). In its report, Glass Lewis notes "the strategic and financial merits of the proposed merger are sound and reasonable" and that "Hess shareholders will have the opportunity to participate in the potential future upside of the combined company." CEO John Hess said: "We are pleased that Glass Lewis recognizes the value of this strategic transaction for shareholders and supports the Board of Directors' unanimous recommendation for our proposed merger with Chevron. We strongly believe that voting FOR the all-stock Chevron transaction now is the best, most accretive value option for our shareholders and look forward to the successful completion of our merger." The company reiterates a number of reasons for Hess shareholders to support the merger. This strategic transaction locks in the value for Hess shareholders at its all-time high price, providing shareholders approximately 15% ownership of a premier supermajor with a world class portfolio of investment opportunities. Increased cash returns including dividends and share repurchases to Hess shareholders upon closing are expected to be nearly 9 times the current level and represent significant additional financial value above the premium paid. Additionally, by combining two strong companies, Hess shareholders will benefit from greater asset and geographic diversification, exposure to a stronger and industry leading balance sheet, the ability to realize various operational and cost synergies, and expanded global partnerships. The proposed all-stock deal allows current Hess shareholders to continue to participate in the upside of Chevron's free cash flow growth.

07:41 EDT Alta Equipment Group announces proposed private offering of senior notes - Alta Equipment Group intends to offer, subject to market and other conditions, $500 million in aggregate principal amount of its senior secured second lien notes due 2029 in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The notes will be guaranteed by all of the Company's domestic subsidiaries and will be secured by a second lien on substantially all of the assets of the Company and its domestic subsidiaries. Concurrent with the closing of the offering, the Company expects to amend and extend its existing $485 million senior secured asset-based revolving credit facility due 2026 and $70 million floor plan facility due 2026 with a $520 million senior secured asset-based revolving credit facility due 2029 and a $90 million floor plan facility due 2029. The First Lien Facilities will be secured by a first-priority lien on the same assets securing the notes. The Company intends to use the net proceeds from the offering, together with the proceeds of new borrowings under the First Lien Facilities, to refinance a portion of the Existing ABL Facility and the Existing Floor Plan Facility prior to the amendments thereto, pay accrued and unpaid interest thereon, and pay related fees and expenses thereto, to redeem all of its outstanding 5.625% Senior Secured Second Lien Notes due 2026, pay the premium, accrued and unpaid interest thereon, and pay related fees and expenses thereto, and for general corporate purposes to the extent there are any remaining proceeds. The offering and related refinancing is expected to be leverage neutral for the Company.

07:38 EDT Nexxen announces $50M Ordinary Share repurchase program - The Company launched a new $50 million Ordinary Share repurchase program on May 7, 2024, following approval from its Lenders which will continue until the earlier of November 1, 2024 and the date the program is completed. The program does not obligate Nexxen to repurchase any particular amount of Ordinary Shares and the program may be suspended, modified, or discontinued at any time at the Company's discretion, subject to applicable law. Upon completion of the current share repurchase program, the Company's Board of Directors intends to evaluate the potential for an additional share repurchase program, subject to then current market conditions and necessary approvals.

07:33 EDT Crown Castle announces Egan-Jones recommended vote 'FOR' nominees - Crown Castle announced that proxy advisory firm Egan-Jones has joined Institutional Shareholder Services in recommending that shareholders vote on the WHITE proxy card or voting instruction form "FOR" ONLY all 12 of Crown Castle's director nominees in connection with the Company's upcoming 2024 Annual Meeting of Shareholders scheduled for May 22, 2024.

07:32 EDT Nature's Miracle and Agrify mutually agree to terminate merger plan - Nature's Miracle (NMHI) and Agrify (AGFY) have mutually agreed to terminate the previously announced plan to merge, originally announced on May 16. Given unfavorable market conditions, a decision was reached to terminate the planned merger and they have also executed a debt termination agreement with entities controlled by Agrify's CEo with respect to the purchase of outstanding debt. No termination or cancellation fees were attached to either party.

07:31 EDT KKR provides $300M corportate credit facility to Origis Energy - KKR, a leading global investment firm and Origis Energy announced that vehicles and accounts managed by KKR's insurance business have KKR, a leading global investment firm and Origis Energy a leading renewable energy and decarbonization solution platform, today announced that vehicles and accounts managed by KKR's insurance business have provided a $300M corporate financing facility to Origis. Proceeds from the facility will support the continued development and construction of Origis' pipeline of solar and storage projects.

07:17 EDT Old Dominion increases quarterly dividend 30% to 26c per share - Old Dominion has declared a quarterly cash dividend of 26c per share of common stock, payable on June 19, to shareholders of record at the close of business on June 5. After giving effect to the company's March two-for-one stock split, this dividend payment represents a 30% increase to the quarterly cash dividend paid in June 2023.

07:15 EDT Envela introduces 'Four Nines' retail concept - Envela Corporation announced the unveiling of its inaugural Four Nines retail store in Gilbert, Arizona. This launch showcases the Company's commitment to bringing physical retail marketplaces for authenticated luxury goods to new communities across the United States. The company said, "Over the past year, the Company has eagerly anticipating this moment, working diligently to create a shopping experience that will connect with customers in the Arizona marketplace. With a focus on exceptional customer service, a wide range of high-quality products, and an inviting store atmosphere, we aim to become a cornerstone of the community. Four Nines offers customers an elevated shopping experience, with new discoveries at every turn. Its curated merchandise aligns with consumer preferences for top brands and current trends, featuring luxury handbags from Louis Vuitton and Gucci, jewelry from Tiffany & Co. and Van Cleef & Arpels, and watches from Rolex and Cartier."

07:14 EDT CyberArk to acquire Venafi from Thoma Bravo for $1.54B in accretive deal - CyberArk (CYBR) announced it has signed a definitive agreement to acquire Venafi, a firm in machine identity management, from Thoma Bravo. This acquisition will combine Venafi's best-in-class machine identity management capabilities with CyberArk's leading identity security capabilities to establish a unified platform for end-to-end machine identity security at enterprise scale. As an innovative leader in PKI and certificate management with a robust presence in modern cloud environments, Venafi offers complementary solutions that and CyberArk's total addressable market TAM by nearly $1B to approximately $60B "This acquisition marks a pivotal milestone for CyberArk, enabling us to further our vision to secure every identityhuman and machine - with the right level of privilege controls," said Matt Cohen, Chief Executive Officer, CyberArk. ...CyberArk intends to acquire Venafi for an enterprise value of approximately $1.54B in a combination of cash and CyberArk shares approximately $1B in cash and approximately $540M in shares . The Boards of Directors of both CyberArk and Venafi have each approved the transaction. The transaction is expected to close in the second half of 2024, subject to required regulatory approvals, clearances and other customary closing conditions. Other details include: Venafi is expected to add approximately $150M annual recurring revenue ARR. Expected to be accretive to non-GAAP margins.

07:11 EDT Arqit Quantum commences cost reduction initiative including headcount reduction - In May 2024, Arqit commenced a cost reduction initiative across all business functions which will include the elimination of significant headcount. These cost reduction actions have begun in accordance with local laws in each of the relevant jurisdictions. Pro forma for the cost reduction initiative, Arqit will have 81 employees as compared to 125 at the end of the reporting period. In addition, the company has undertaken actions to rationalize its office space to further reduce costs. These cost reduction initiatives are expected to result in a 40% decrease in monthly budgeted operating costs to approximately $1.8 million commencing July from previously budgeted monthly operating costs of approximately $3.0 million.As of 31 March 2024, Arqit had $21.3 million of cash and cash equivalents.

07:10 EDT Entero Therapeutics presents two posters on celiac disease research at DDW 2024 - Entero Therapeutics yesterday presented two posters on celiac disease research at the 2024 Digestive Disease Week, DDW 2024, Conference in Washington, D.C. The presentations draw upon research from the robust clinical program investigating latiglutenase, an oral biotherapeutic being developed as a potentially first-in-class, targeted, oral biotherapeutic for celiac disease, CeD. The results from these presentations demonstrate potential for improved CeD diagnostics and clinical trial design. "These findings will enable us to better monitor celiac disease and refine the tools we use in its diagnosis," said Jack Syage, Ph.D., President and Chief Scientific Officer of Entero Therapeutics. "The data that indicates significantly higher levels of gluten are required to revert serology to positive in CeD patients underscores a fundamental gap in our diagnostic capabilities."

07:08 EDT CGI Inc. selected by UK ESMCP as delivery partner - CGI has been selected by the UK Government's Home Office as the Technology Delivery Partner for the Emergency Services Mobile Communications Programme, or ESMCP, across England, Scotland and Wales. The five-year contract, which focuses on advisory and delivery capability, is valued at CA$81.2M.

07:06 EDT TFF, Cleveland Clinic to advance multivalent universal influenza vaccines - TFF Pharmaceuticals announced that, in collaboration with Cleveland Clinic, the Company is advancing multiple multivalent universal influenza vaccines to protect against seasonal and pandemic viruses into preclinical testing. The decision to advance the vaccine candidates into preclinical testing was based upon the successful completion of formulation testing with stability data on the combination of hemagglutinin antigens with four different adjuvants. Based on these data, three HA antigen/adjuvant candidate vaccines have been selected for testing in a pre-clinical model at Cleveland Clinic Florida. "A recent survey of infectious disease specialists presented at this year's ESCMID Global Congress indicates that influenza could represent the next pandemic threat to the global population," said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. "Working in collaboration with Dr. Ted M. Ross and his colleagues, our goal is to develop a shelf-stable mucosal vaccine with unique characteristics for inhalational delivery and would circumvent the need for cold chain storage which could significantly improve the availability and distribution of potentially life-saving medicine."

07:05 EDT PTC Therapeutics: EC returns Translarna opinion to CHMP for re-evaluation - PTC Therapeutics announced that the European Commission has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna and has returned the opinion to the CHMP for re-evaluation. As a result, Translarna remains on the market and available for patients in Europe consistent with its current marketing authorization. The EC has asked the CHMP to further consider the totality of evidence, including data from patient registries and real-world evidence, in a revised opinion. "The maintenance of the current authorization of Translarna is a big win for boys and young men with nonsense mutation Duchenne muscular dystrophy in Europe," said Matthew B. Klein, M.D., CEO PTC Therapeutics. "The efficacy and safety demonstrated in clinical trials and the long-term STRIDE registry support that Translarna fills an otherwise unmet need for nmDMD patients. We look forward to working collaboratively with CHMP on next steps once they are defined." In addition, the European Medicines Agency has informed PTC that the decision has been taken to consider the Scientific Advisory Group meeting for Translarna held on September 5, 2023, and all the procedural steps that followed, as invalid. Furthermore, the input from the SAG meeting held in September 2023 as well as the meeting held in January 2024 will not be considered by the CHMP in any future evaluation of Translarna. Given the inability to accurately forecast the upside impact of the continued authorization of Translarna in Europe on 2024 revenue, PTC will pause 2024 total revenue guidance at this time. Guidance will be updated at a future date.

06:57 EDT Aesthetic Medical receives delisting decision from Nasdaq hearings panel - Aesthetic Medical announced that it has received a determination letter of the Hearings Panel of The Nasdaq Capital Market dated May 17, 2024, notifying the Company that the Panel determined to delist the Company's securities from Nasdaq, due to the failure to satisfy the continued listing conditions as previously disclosed. As a result, the Company expects that its securities will be suspended from trading at the open of business on May 21, 2024 and delisted from Nasdaq after the completion of Nasdaq's filing of a Form 25 Notification of Delisting with the SEC after all appeal periods have expired. The Company does not intend to file an appeal of the determination. Following the delisting, the Company expects that its American Depositary Shares will be quoted on the "over the counter" market operated by OTC Markets Group so that a trading market may continue to exist for its ADSs. There is no guarantee, however, that a broker will continue to make a market in the ADSs and that trading of the ADSs will continue on an OTC market or otherwise. The delisting from Nasdaq will have no significant impact on the Company's operations in the aesthetic medical industry in mainland China. The Company is committed to enhancing operational management and efficiency and aims to drive performance growth.

06:51 EDT ANI Pharmaceuticals launches Kionex suspension - ANI Pharmaceuticals announced the launch of Kionex for Oral or Rectal use. Kionex Suspension is the only commercially available therapeutically equivalent to the reference listed drug SPS Suspension for Oral or Rectal use. U.S. annual sales for Sodium Polystyrene Sulfonate Oral / Rectal Suspension total approximately $30.3M, based on March 2024 moving annual total IQVIA data.

06:37 EDT Dyne Therapeutics' DYNE-101 shows efficacy in two Phase 1/2 trials - Dyne Therapeutics announced positive clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 - DM1 - and its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy or DMD who are amenable to exon 51 skipping. New data from both trials demonstrated impact on key disease biomarkers as well as improvement in multiple functional endpoints and favorable safety profiles. In the ACHIEVE trial, DYNE-101 demonstrated robust muscle delivery and dose-dependent, consistent splicing correction while also showing improvement in multiple functional endpoints and patient reported outcomes. Dyne also reported safety and tolerability data from 56 patients enrolled through the 6.8 mg/kg Q8W cohort of the MAD portion of the ACHIEVE trial. DYNE-101 demonstrated a favorable safety profile. The majority of treatment emergent adverse events were mild or moderate and no related serious treatment emergent adverse events have been identified. In the Phase 1/2 DELIVER trial of DYNE-251 in DMD, 10 mg/kg of DYNE-251 Q4W demonstrated dose-dependent exon skipping and dystrophin expression. Dyne plans to continue to engage with global regulators this year on ACHIEVE and DELIVER, and anticipates providing an update on the path to registration for both DYNE-101 and DYNE-251 by the end of 2024. Both trials are designed to be registrational, and the company is pursuing expedited approval pathways for both programs. In DM1, Dyne continues to pursue an accelerated approval pathway for DYNE-101, including leveraging splicing as a potential surrogate biomarker. In DMD, Dyne has confirmed that the FDA precedent for using dystrophin as a surrogate biomarker for accelerated approval remains available. Dyne expects to provide updates on programs, including facioscapulohumeral muscular dystrophy and other pipeline opportunities during 2024.

06:13 EDT NextDecade signs offtake and equity agreement with Abu Dhabi's ADNOC - NextDecade and ADNOC, a diversified energy and petrochemicals group wholly owned by the Emirate of Abu Dhabi, announced the acquisition by ADNOC of a 11.7% stake in Phase 1 of NextDecade's Rio Grande LNG, a liquefied natural gas export project located in Texas, expected to produce a less carbon-intensive LNG. Additionally, ADNOC and NextDecade have entered into a 20-year LNG offtake agreement from RGLNG Train 4. The Phase 1 RGLNG equity stake has been acquired through an investment vehicle of Global Infrastructure Partners, an infrastructure investor. ADNOC acquired a portion of GIP's existing equity interest in Phase 1 while NextDecade retains its expected economic interest in Phase 1 as well as its interests in the Train 4 and Train 5 expansion capacity. The Phase 1 acquisition marks ADNOC's first strategic investment in the US. The 20-year LNG offtake agreement between ADNOC and NextDecade is for 1.9 million tons per annum from RGLNG Train 4, on FOB basis at a price indexed to Henry Hub, subject to a Final Investment Decision. Rio Grande LNG, situated on a 984-acre site near Brownsville, Texas, is the first US LNG project offering expected emissions reduction of more than 90% through its proposed carbon capture and storage project, expected to capture and permanently store more than 5 million metric tons per annum of CO2. NextDecade is currently targeting FID on Train 4 at the Rio Grande LNG Facility in the second half of 2024.

06:08 EDT Fractyl Health's Rejuva pancreatic gene therapy shows efficacy in presentation - Fractyl Health presented new data from its preclinical Rejuva pancreatic gene therapy program as part of an oral presentation at Digestive Disease Week 2024 in Washington, D.C. In the presentation, data showed that Rejuva reduced liver weight by 42% and liver triglyceride content by 67% vs. placebo two months after administration. Data also showed a reduction of 36% in total cholesterol and 51% in LDL cholesterol compared to placebo two months after administration. These results indicate the potential impact of this GLP-1 PGTx candidate to alleviate cardiovascular risk associated with increased levels of cholesterol. Rejuva is the company's modular, physiologic gene therapy platform with three elements designed to enable successful pancreatic gene therapy: a proprietary delivery catheter designed to enable local, low-dose, therapeutic delivery directly to the pancreas via endoscopic access, vectors with tropism for the pancreatic islet to enable successful transduction and gene delivery with limited biodistribution, and transgenes with tissue-restricted promoters and metabolically active peptides that can durably impact glucose and weight control.

06:04 EDT Arrowhead announces new interim clinical data on ARO-RAGE - Arrowhead Pharmaceuticals announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society 2024 International Conference. Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE concentration in bronchoalveolar lavage fluid and serum in a dose-dependent manner in normal healthy volunteers and in patients with mild to moderate asthma. "These results underscore the potential of our proprietary TRiMTM platform to enable us to develop impactful new therapies to potentially treat multiple pulmonary diseases with significant unmet needs. Arrowhead was the first company to show that RNAi could be harnessed to achieve high levels of target gene knockdown in the lung in healthy human subjects and these data presented at ATS 2024 build on that success," said James Hamilton, M.D., chief of discovery and translational medicine at Arrowhead. "Our ARO-RAGE data is first-in-class and demonstrated deep and sustained knockdown in the lung in patients with mild to moderate asthma, a long duration of effect that appears to support every two-month dosing, and a favorable safety and tolerability profile. These results give us further confidence as we move towards the initiation of a Phase 2 study in late 2024."

06:02 EDT MediciNova receives Notice of Allowance for new patent covering MN-166 - MediciNova announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 for the prevention of metastasis of eye cancer. Once issued, this patent is expected to expire no earlier than July 2042. The allowed claims cover the use of MN-166 for preventing, ameliorating, or minimizing metastasis of eye cancer. The allowed claims specifically cover the use of MN-166 for preventing, ameliorating, or minimizing metastasis of uveal melanoma. The allowed claims cover oral administration, a wide range of doses, a range of different dosing frequencies, and a range of different treatment periods.

05:36 EDT Zai Lab, Innoviva announce China NMPA approval for Xacduro - Zai Lab (ZLAB )and Innoviva (INVA) announced that China's National Medical Products Administration, or NMPA, has approved Zai Lab's New Drug Application (NDA) for Xacduro for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.